HFA-134a

DRUG3 trials

Sponsors

AstraZeneca, GlaxoSmithKline

Conditions

AsthmaMucociliary Clearance

Phase 1

Study of the Effect of HFA-152a and HFA-134a Propellants on Mucociliary Clearance in Healthy Participants

CompletedNCT06506266

GlaxoSmithKlineAsthma

Start: 2024-07-29End: 2024-10-24Updated: 2026-04-14

Phase 3

Study to Assess Effect of Next-Generation Propellant MDI on Mucociliary Clearance Vs. HFA Propellant MDI in Healthy Participants

CompletedNCT05755932

AstraZenecaMucociliary Clearance

Start: 2023-06-14End: 2024-07-22Updated: 2026-02-25

A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)

Not yet recruitingNCT07645248

GlaxoSmithKlineAsthma

Start: 2026-09-15End: 2027-02-25Target: 110Updated: 2026-06-12

Related Papers

Developing low-carbon metered-dose inhalers: effects of propellant HFA-152a on mucociliary clearance and bronchoconstriction in two Phase 1 randomised trials.

2026-07-21

Mucociliary Clearance Following a Next-Generation Propellant Versus Hydrofluoroalkane-134a via Pressurized Metered-Dose Inhaler: A Randomized, Double-Blind, Two-Way Crossover Study in Healthy Adults

Journal of Aerosol Medicine and Pulmonary Drug Delivery2026-07-16